ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Kansas City, KS, USA:

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Tafasitamab

Phase 1, Phase 2

Celgene
Celgene

Overland Park, Kansas, United States and 88 other locations

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Kansas City, Kansas, United States and 66 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Prednisone
Drug: Lenalidomide

Phase 2

Genmab
Genmab

Kansas City, Missouri, United States and 74 other locations

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Enrolling
Hodgkin Lymphoma, Adult
Hodgkin Lymphoma
Drug: MT-601

Phase 1

Marker Therapeutics

Kansas City, Kansas, United States and 6 other locations

ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non...

Enrolling
Mature B-Cell Non-Hodgkin Lymphoma
Drug: Ifosfamide
Drug: Rituximab

Phase 1, Phase 2

Roche
Roche

Kansas City, Missouri, United States and 21 other locations

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK...

Enrolling
Non-Hodgkin's Lymphoma
Drug: Glofitamab
Drug: Obinutuzumab

Phase 1, Phase 2

Roche
Roche

Kansas City, Kansas, United States and 40 other locations

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malig...

Active, not recruiting
B-cell Lymphoma
Non-Hodgkin Lymphoma
Biological: CTX110

Phase 1, Phase 2

CRISPR Therapeutics

Westwood, Kansas, United States and 32 other locations

SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory bioma...

Enrolling
Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Drug: SC291

Phase 1

Sana Biotechnology

Fairway, Kansas, United States and 7 other locations

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Celgene
Celgene

Fairway, Kansas, United States and 125 other locations

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...

Active, not recruiting
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Drug: Venetoclax
Drug: Rituximab

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Kansas City, Kansas, United States and 55 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems